2138442-31-4
2138442-31-4
Chemical Structure
Plamotamab
Synonym(s): XmAb-13676
- CAS No.: 2138442-31-4
- Formula:N/A
- Molecular Weight:(124.88 kDa)
IUPAC Name: (Z)-2-(tert-butylimino)-5-phenyl-3-(propan-2-yl-1,1,1,3,3,3-d6)-1,3,5-thiadiazinan-4-one
SMILES: [plamotamab]
Biological Activity: Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Plamotamab | 99.12% | Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Parrondo RD, et al. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742. [Content Brief]
- [2]. Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.
Keywords
